Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Bortezomib (Velcade®, PS-341) and Docetaxel for Patients With Hormone Refractory Prostate Cancer

NCT00183937 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT00183937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00183937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Bortezomib (Velcade®, PS-341) and Docetaxel for Patients With Hormone Refractory Prostate Cancer
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2005
Completion date
June 11, 2012
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer